Akouos IPO Presentation Deck

Deep Pipeline Highlights Breadth of Platform 32 Product Candidate or Development Program (Indication) Hair Cells AK-OTOF (OTOF-Mediated Hearing Loss) CLRN1 / Usher Type 3A Autosomal Dominant Hearing Disorder Supporting Cells GJB2 Hair Cell Regeneration Secreted Proteins AK-antiVEGF (Vestibular Schwannoma) AAV-Enabled Modalities: Estimated Prevalence (US and EU) 20.000 2,000 Pending Target Selection 200,000 Pending Target Selection 200,000 Gene Transfer Discovery Gene Transfer + Knockdown Stage of Development CONFIDENTIAL Preclinical Phase 1/2 Therapeutic Protein Expression Pivotal Next Planned Milestone AKOUOS IND Submission * Candidate Selection Target Announcement Candidate Selection Target Announcement Pre-IND Meeting

View entire presentation